IL319360A - Novel compounds as modulators of nlrp3 inhibition - Google Patents
Novel compounds as modulators of nlrp3 inhibitionInfo
- Publication number
- IL319360A IL319360A IL319360A IL31936025A IL319360A IL 319360 A IL319360 A IL 319360A IL 319360 A IL319360 A IL 319360A IL 31936025 A IL31936025 A IL 31936025A IL 319360 A IL319360 A IL 319360A
- Authority
- IL
- Israel
- Prior art keywords
- modulators
- novel compounds
- nlrp3 inhibition
- nlrp3
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22211843 | 2022-12-07 | ||
| EP23173506 | 2023-05-16 | ||
| PCT/EP2023/084200 WO2024121086A1 (en) | 2022-12-07 | 2023-12-05 | Novel compounds as modulators of nlrp3 inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319360A true IL319360A (en) | 2025-05-01 |
Family
ID=89073246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319360A IL319360A (en) | 2022-12-07 | 2023-12-05 | Novel compounds as modulators of nlrp3 inhibition |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20260200901A1 (en) |
| EP (1) | EP4630417A1 (en) |
| JP (1) | JP2025540202A (en) |
| KR (1) | KR20250116028A (en) |
| CN (1) | CN120322432A (en) |
| AR (1) | AR131278A1 (en) |
| AU (1) | AU2023388532A1 (en) |
| CL (1) | CL2025001654A1 (en) |
| CO (1) | CO2025007108A2 (en) |
| CR (1) | CR20250215A (en) |
| IL (1) | IL319360A (en) |
| MX (1) | MX2025005972A (en) |
| PE (1) | PE20251845A1 (en) |
| TW (1) | TW202440554A (en) |
| WO (1) | WO2024121086A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| TW202545527A (en) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3 and glp-1a combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (en) * | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
| LT4337652T (en) * | 2021-05-12 | 2025-06-25 | F. Hoffmann-La Roche Ag | Nlrp3 inhibitors |
| EP4347571B1 (en) * | 2021-06-04 | 2026-04-22 | F. Hoffmann-La Roche AG | Triazine derivatives and their use in the treatment of cancer. |
-
2023
- 2023-12-05 JP JP2025532577A patent/JP2025540202A/en active Pending
- 2023-12-05 KR KR1020257018576A patent/KR20250116028A/en active Pending
- 2023-12-05 PE PE2025001111A patent/PE20251845A1/en unknown
- 2023-12-05 AU AU2023388532A patent/AU2023388532A1/en active Pending
- 2023-12-05 WO PCT/EP2023/084200 patent/WO2024121086A1/en not_active Ceased
- 2023-12-05 EP EP23817457.7A patent/EP4630417A1/en active Pending
- 2023-12-05 AR ARP230103308A patent/AR131278A1/en unknown
- 2023-12-05 CR CR20250215A patent/CR20250215A/en unknown
- 2023-12-05 US US19/135,999 patent/US20260200901A1/en active Pending
- 2023-12-05 CN CN202380084408.9A patent/CN120322432A/en active Pending
- 2023-12-05 IL IL319360A patent/IL319360A/en unknown
- 2023-12-06 TW TW112147546A patent/TW202440554A/en unknown
-
2025
- 2025-05-22 MX MX2025005972A patent/MX2025005972A/en unknown
- 2025-05-29 CO CONC2025/0007108A patent/CO2025007108A2/en unknown
- 2025-06-04 CL CL2025001654A patent/CL2025001654A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025005972A (en) | 2025-06-02 |
| JP2025540202A (en) | 2025-12-11 |
| US20260200901A1 (en) | 2026-07-16 |
| CR20250215A (en) | 2025-06-26 |
| EP4630417A1 (en) | 2025-10-15 |
| AU2023388532A1 (en) | 2025-02-13 |
| TW202440554A (en) | 2024-10-16 |
| AR131278A1 (en) | 2025-03-05 |
| CN120322432A (en) | 2025-07-15 |
| WO2024121086A1 (en) | 2024-06-13 |
| PE20251845A1 (en) | 2025-07-17 |
| CO2025007108A2 (en) | 2025-06-16 |
| KR20250116028A (en) | 2025-07-31 |
| CL2025001654A1 (en) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL317736A (en) | Compounds as inhibitors of axl | |
| IL287472A (en) | Crystal form of wee1 inhibitor compound and use thereof | |
| EP4153591A4 (en) | METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS | |
| IL308071A (en) | Process for the preparation of nlrp3 inhibitors | |
| EP4271402A4 (en) | Composition of bl-8040 | |
| IL314824A (en) | Combination formulation of cedazuridine | |
| GB202411655D0 (en) | Application of circHIF1a | |
| GB202307924D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| CA3273582A1 (en) | Novel compounds as modulators of nlrp3 inhibition | |
| IL317047A (en) | Solid forms of heterocyclylamides as irak4 inhibitors | |
| EP4262795A4 (en) | Synthesis of structural analogs of largazole and associated compounds | |
| HK40106117A (en) | Tricyclic compounds as inhibitors of kras | |
| HK40083546A (en) | Tricyclic compounds as inhibitors of kras | |
| TWI926416B (en) | Inhibitor compounds for selective passivation of surfaces | |
| HK40087466A (en) | Crystal form of azetidine-substituted compound | |
| GB202311665D0 (en) | Modification of composition | |
| GB201910665D0 (en) | Novel form of compounds | |
| HK40121003A (en) | Compounds as inhibitors of axl | |
| IL317021A (en) | Synthesis of fluorosilyl compounds | |
| IL321066A (en) | Proccesses for the preparation of an nlrp3 inhibitor | |
| GB202314050D0 (en) | Novel form of bemcentinib | |
| GB202114327D0 (en) | Uses of terpenophenolic compounds | |
| CA3280638A1 (en) | Inhibitors of nlrp3 | |
| CA3266364A1 (en) | Use of heteroaryloxynaphthalene compound |